Symbiomix Therapeutics appoints David L. Stern as CEO
Mr. Stern brings to Symbiomix more than 20 years of leadership in strategic planning, business development, reimbursement strategy, and marketing and sales.
Mr. Stern is an independent board member of California Cryobank, a provider of reproductive and stem cell services in the US.
Previously, he was Chief Commercial Officer of Celmatix, a personalized medicine company focused on fertility and women’s health.
Before joining Celmatix, Mr. Stern was Executive Vice President of Global Commercial Operations for OvaScience, where he was responsible for the global launch of the company’s first new fertility treatment, Augment.
He also served as Senior Vice President and Head of Global Business as well as other leadership positions for fertility at Merck Serono, and was director of reproductive marketing at Organon USA, responsible for the company’s contraceptive and fertility portfolio.
Mr. Stern has an MBA from the F.W. Olin School of Business at Babson College, and a Bachelor’s degree in biology from Brandeis University.
He is a member of the European Society for Human Reproduction and Embryology and the American Society for Reproductive Medicine. ■
LATEST MOVES FROM New Jersey
- New Jersey Resources names Maureen Borkowski to board
- Milestone Scientific appoints Daniel Goldberger as CEO
- Celldex changes management team
- Pacira Pharmaceuticals appoints Mark I. Froimson to board
- CytoSorbents appoints Eric G. Mortensen as CMO
More inside POST